RxDoctor Payments DataLook up a doctor →

Kittredge Baldwin, DO

Pulmonary Disease · Silverdale, WANPI 1285683516

Payments from drug & device makers

$9,955in general payments, 2019–2025

Across 529 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Sanofi$1K
  • Grifols USA, LLC$795
  • Boehringer Ingelheim$516
  • Regeneron Healthcare Solutions, Inc.$503
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$9,75098%
  • Education$2052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,955 in reported general payments places this provider in the 80th percentile of 275 pulmonary disease providers in Washington.

See all pulmonary disease providers in Washington

Medicare billing

Part B allowed, 2024
$217,086
Medicare patients
829
Services billed
2,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter374$522,466
Breo ElliptaFluticasone/Vilanterol117$84,912
Spiriva RespimatTiotropium Bromide51$63,247
Dupixent PenDupilumab15$55,862
XareltoRivaroxaban30$31,998
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$30,988
Advair HfaFluticasone Propion/Salmeterol33$28,665
Fluticasone-SalmeterolFluticasone Propion/Salmeterol120$28,479
Spiriva HandihalerTiotropium Bromide21$25,936
Albuterol Sulfate HfaAlbuterol Sulfate308$20,579
DuleraMometasone/Formoterol26$17,887
Combivent RespimatIpratropium/Albuterol Sulfate12$16,756
Ambrisentan12$15,169
Incruse ElliptaUmeclidinium Bromide22$14,864
SymbicortBudesonide/Formoterol Fumarate38$11,253

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,357$622,243513 claims
Boehringer IngelheimSpiriva Respimat, Combivent Respimat$516$80,00363 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,971$42,24159 claims
Johnson & JohnsonXarelto$94$31,99830 claims
MerckDulera$91$17,88726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 275 pulmonary disease providers in Washington.

Other pulmonary disease in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →